Novel anti-hormonal therapy may be a new treatment option for early-stage breast canc

[News]

Early results from a UCLA-led clinical trial found treating women with estrogen receptor (ER)-positive and human epidermal growth factor receptor-2 (HER2)-negative early breast cancers with a novel type of anti-hormonal therapy, called an oral selective estrogen receptor degrader (SERD), led to clinically meaningful reductions in tumor activity prior to surgery.

More... (https://www.news-medical.net/news/20210921/Novel-anti-hormonal-therapy-may-be-a-new-treatment-option-for-early-stage-breast-cancer.aspx)